Compare Northrop Grumman Corporation (NOC) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Novavax Inc — how do they compare? Northrop Grumman Corporation trades at $481.34 (market cap $68.83B), while Novavax Inc trades at $11.09 (market cap $1.82B). The key difference: Northrop Grumman Corporation is far larger — about 37.8× Novavax Inc's market cap, and Northrop Grumman Corporation pays a 2.04% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 81 Days and Novavax Inc for 59 Days on average.
| NOC | NVAX | |
|---|---|---|
Market Cap | $68.83B | $1.82B |
Volume | 1,081,989 | 6,198,505 |
Sector | Industrials | Health |
52-Week High | $768.02 | $12.56 |
52-Week Low | $473.46 | $6.22 |
Typical Hold Time | 81 Days | 59 Days |
Enterprise Value | $82.81B | $1.39B |
Dividend Yield | 2.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $479.00, up 1.17% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $7.68 exceeding expectations, supported by a robust $104.7 billion backlog and expanding defense budgets. Recent news highlights both competitive pressures from Boeing's $20B fighter contract win and positive developments in F-35 radar demand.
The investment outlook remains positive with analyst consensus at $600.62 (25% upside) and 54% buy ratings, though technical indicators suggest near-term pressure. Key risks include contract competition and execution challenges on major programs like the B-21 bomber, while strong cash flow generation and dividend growth provide shareholder support.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
